Browse by Poster Presenter

Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

C
Callegari, Ernesto

Pfizer, Inc.
PII-176 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ZAVEGEPANT
Ernesto Callegari
Favorite
PII-177 - PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE GASTRIC ACID MODIFIER EFFECT ON RIMEGEPANT EXPOSURE
Ernesto Callegari
Favorite
Cardona, Panli

Amgen, Inc
PII-047 - AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB IN THE FED AND FASTED STATE
Panli Cardona
Favorite
Carver, Kathryn

Northwestern University
PII-079 - IDENTIFYING EPIGENTIC INFLUENCES ON DRUG METABOLISM: MULTI-OMIC ANALYSES IN AFRICAN AMERICAN HEPATOCYTES
Kathryn Carver
Favorite
Chae, Woori

Seoul National University
PII-005 - A NOVEL ENDOTYPE OF ADULT ASTHMA SUGGESTED BY PLASMA METABOLITE PROFILING OF THE COHORT FOR REALITY AND EVOLUTION OF ADULT ASTHMA IN KOREA (COREA)
Woori Chae
Favorite
Chang, Min Jung

Yonsei University
AI-006 - DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES
Min Jung Chang
Favorite
LB-010 - DEEP LEARNING PREDICTION OF VANCOMYCIN TIME-CONCENTRATION LEVELS IN NEONATES
Min Jung Chang
Favorite
Channavazzala, Madhav

Vantage Research
PII-212 - A QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR PREDICTING EFFICACY FOR A COMBINATION OF AN ANTIBODY DRUG CONJUGATE (ADC) AND A CHECKPOINT INHIBITOR (CPI) IN PHASE II/III CLINICAL TRIALS
Madhav Channavazzala
Favorite
Chekka, Lakshmi Manasa

U.S. Food and Drug Administration
PT-015 - EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY
Lakshmi Manasa Chekka
Favorite
PWII-002 - EVALUATING THE UTILITY OF PROTEOMICS FOR IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILARITY - USING PCSK-9 INHIBITOR BIOLOGICS AS A CASE STUDY
Lakshmi Manasa Chekka
Favorite
Cheng, Yiming

Bristol Myers Squibb
AI-001 - APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS
Yiming Cheng
Favorite
PII-098 - APPLICATION OF GAUSSIAN PROCESS MODEL IN LONGITUDINAL PHARMACOKINETIC/PHARMACODYNAMIC DATA AND COMPARISON WITH NATURAL LANGUAGE PROCESSING MODELS
Yiming Cheng
Favorite
Chen, Huili

Univ of Florida Coll of Pharmacy
LB-037 - UTILIZING MODEL BASED META-ANALYSIS TO CHARACTERIZE BREAKTHROUGH BLEEDING AND SPOTTING IN WOMEN USING HORMONAL CONTRACEPTIVES
Huili Chen
Favorite
Chen, Jie

University of Houston
LB-034 - THE POPULATION PHARMACOKINETICS STUDY OF ANTI-TUMOR B AMONG HEALTHY VOLUNTEER AND ORAL CANCER PATIENTS TO INFORM DOSE DECISION
Jie Chen
Favorite
Chen, Min

Bristol Myers Squibb
PII-027 - FORMULATION IMPACT OF SSZ ON MTX EXPOSURE: A REPEAT DDI STUDY FOR A MK2 INHIBITOR BMS-986371
Min Chen
Favorite
Chen, Yizhe

Clinical pharmacology and pharmacometrics, disposition and bioanalysis
PII-116 - EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Yizhe Chen
Favorite
Cilliers, Cornelius

Mirati Therapeutics
PII-195 - A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION.
Cornelius Cilliers
Favorite
PII-196 - A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL RENAL FUNCTION.
Cornelius Cilliers
Favorite
Clemens, Lara

Simulations Plus, Inc.
PII-210 - A BIOMARKER-FOCUSED QSP MODEL OF COMPLEMENT ALTERNATIVE AND TERMINAL PATHWAYS TO EVALUATE POTENTIAL TARGETS FOR THERAPEUTIC IMPACT IN COMPLEMENT-ASSOCIATED DISEASES: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS A CASE STUDY.
Lara Clemens
Favorite
Collins, Keagan

Pfizer, Inc.
PII-064 - POPULATION PHARMACOKINETIC MODEL FOR THE TGFβR1 INHIBITOR PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Keagan Collins
Favorite
Collins, Kimberly

Critical Path Institute
PII-008 - C-PEPTIDE DISEASE PROGRESSION MODEL IN INDIVIDUALS WITH NEW-ONSET TYPE 1 DIABETES
Kimberly Collins
Favorite
Crass, Ryan

Apellis Pharmaceuticals
PII-096 - A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.
Ryan Crass
Favorite
PWI-002 - A TRANSLATIONAL MODELING AND SIMULATION APPROACH TO INFORM FIRST-IN-HUMAN DOSE SELECTION FOR AN SIRNA TARGETING COMPLEMENT C3.
Ryan Crass
Favorite